Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Melanoma 3Medulloblastoma 3Ependymoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Gliosarcoma 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Recurrence 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × 1-methyltryptophan × Clear all
NCT02460367 2022-04-06

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Lumos Pharma

Phase 1 Terminated
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡